SI-BONE, Inc. (SIBN) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

SI-BONE, Inc. (SIBN) Healthcare & Pipeline Overview

SI-BONE, Inc. develops and markets implantable medical devices for sacropelvic disorders, focusing on its iFuse system for sacroiliac joint dysfunction. With a direct sales force and distributors, the company addresses a specific niche within the broader medical device landscape, holding a significant position in the SI joint fusion market.

What Is the Investment Thesis for SIBN?

SI-BONE's investment thesis centers on the growing prevalence of SI joint dysfunction and the increasing adoption of minimally invasive surgical techniques. The company's iFuse Implant System offers a compelling alternative to traditional open surgery, potentially leading to faster recovery times and reduced complications. With a gross margin of 79.6%, SI-BONE demonstrates strong pricing power and efficient operations. Key growth catalysts include expanding market awareness of SI joint dysfunction, increasing adoption of iFuse by surgeons, and continued innovation in implant technology. However, the company's negative profit margin of -9.4% and reliance on a single product line represent potential risks.

Based on FMP financials and quantitative analysis

SIBN Key Highlights

SI-BONE operates in the medical device industry, specifically focusing on solutions for sacroiliac joint dysfunction.

• The company's primary product, the iFuse Implant System, is a minimally invasive surgical device.
• SI-BONE markets its products through a direct sales force and distributors.
• The company was founded in 2008 and is headquartered in Santa Clara, California.
• SI-BONE has a market capitalization of $814M.

Who Are SIBN's Competitors?

SIBN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SIBN's Key Strengths?

Proprietary iFuse technology with clinical evidence of efficacy.

• Established presence in the SI joint fusion market.
• Direct sales force providing specialized expertise.
• Strong gross margin of 79.6%.

What Are SIBN's Weaknesses?

Reliance on a single product line (iFuse).

• Negative profit margin (-9.4%).
• Limited geographic diversification.
• Relatively small market capitalization ($814M).

What Could Drive SIBN Stock Higher?

Publication of new clinical studies demonstrating the long-term efficacy of iFuse.

• Expansion into new geographic markets, such as Europe and Asia.
• Increasing awareness of SI joint dysfunction among physicians and patients.
• Continued innovation in implant technology and surgical techniques.

What Are the Key Risks for SIBN?

Negative return on equity (-8.2%) — the business is not currently generating profit on shareholder capital.

• Insider selling — insiders were net sellers of roughly $4.1M recently.
• Competition from established medical device companies with greater resources.
• Technological advancements that could render iFuse obsolete.
• Changes in reimbursement policies that could reduce the attractiveness of iFuse.
• Product liability claims related to the iFuse Implant System.

What Are the Growth Opportunities for SIBN?

• Expanding market awareness and adoption of iFuse: SI-BONE has the opportunity to further penetrate the existing market by increasing awareness of SI joint dysfunction and the benefits of the iFuse Implant System among both physicians and patients. This can be achieved through targeted marketing campaigns, educational programs, and clinical studies demonstrating the efficacy of iFuse. The market for SI joint fusion is estimated to be substantial, with significant potential for growth as awareness increases.
• Developing and launching new products: SI-BONE can drive growth by expanding its product portfolio to address a wider range of sacropelvic disorders. The company's iFuse-3D and iFuse-TORQ implants represent steps in this direction, and further innovation in implant design and materials could create new market opportunities. This includes exploring new applications for 3D-printing technology in orthopedic implants.
• Expanding geographically: SI-BONE currently markets its products in the United States and internationally. Expanding into new geographic markets, particularly in Europe and Asia, represents a significant growth opportunity. This would require establishing distribution networks, obtaining regulatory approvals, and adapting its marketing strategies to local market conditions. The global market for orthopedic implants is substantial and growing, offering ample opportunities for SI-BONE.
• Securing favorable reimbursement policies: Reimbursement policies play a critical role in the adoption of medical devices. SI-BONE can drive growth by working with payers to secure favorable reimbursement rates for the iFuse Implant System. This requires demonstrating the cost-effectiveness of iFuse compared to traditional treatments and providing clinical evidence of its efficacy. Positive reimbursement policies can significantly increase the accessibility of iFuse to patients.
• Acquiring or partnering with complementary businesses: SI-BONE could accelerate its growth by acquiring or partnering with companies that offer complementary products or technologies. This could include companies specializing in pain management, rehabilitation, or other areas of orthopedic surgery. Such acquisitions or partnerships could expand SI-BONE's product portfolio, broaden its customer base, and enhance its market position.

What Are SIBN's Competitive Advantages?

• Proprietary iFuse Implant System with a unique design.
• Established presence in the sacroiliac joint fusion market.
• Direct sales force providing specialized expertise and support.
• Intellectual property protection for its products and technologies.

What Does SIBN Do?

SI-BONE, Inc., founded in 2008 and headquartered in Santa Clara, California, is a medical device company dedicated to developing and commercializing innovative solutions for patients suffering from musculoskeletal disorders of the sacropelvic anatomy. The company's flagship product is the iFuse Implant System, a minimally invasive surgical (MIS) device designed to treat sacroiliac (SI) joint dysfunction and degeneration. SI-BONE's iFuse system provides a unique approach to SI joint fusion, offering patients a less invasive alternative to traditional open surgery. The company has expanded its product line to include iFuse-3D, a titanium implant featuring a 3D-printed porous surface, and iFuse-TORQ, a set of 3D-printed threaded implants for pelvic fractures and SI joint fusion. SI-BONE markets its products through a direct sales force and a network of distributors, reaching healthcare providers and patients across the United States and internationally. The company's focus on the SI joint market has allowed it to establish a strong presence and become a key player in this specialized area of orthopedic surgery.

What Products and Services Does SIBN Offer?

• Develops implantable medical devices for sacropelvic disorders.
• Offers the iFuse Implant System for sacroiliac joint dysfunction.
• Provides minimally invasive surgical solutions.
• Markets products through a direct sales force and distributors.
• Offers iFuse-3D, a titanium implant with a 3D-printed porous surface.
• Provides iFuse-TORQ, a set of 3D-printed threaded implants for pelvic fractures.

How Does SIBN Make Money?

• Develops and manufactures implantable medical devices.
• Sells products directly to hospitals and surgeons through a direct sales force.
• Utilizes distributors to reach international markets and expand market coverage.

What Industry Does SIBN Operate In?

The medical device industry is characterized by rapid innovation, stringent regulatory requirements, and intense competition. SI-BONE operates within the orthopedic segment, specifically targeting the sacroiliac joint fusion market. This market is driven by the increasing prevalence of SI joint dysfunction, an aging population, and a growing demand for minimally invasive surgical procedures. SI-BONE competes with other medical device companies offering SI joint fusion solutions, as well as with traditional open surgery techniques. The company's focus on innovation and its established presence in the SI joint market position it favorably within the industry.

Who Are SIBN's Key Customers?

• Hospitals and surgical centers.
• Orthopedic surgeons specializing in sacropelvic disorders.
• Patients suffering from sacroiliac joint dysfunction, adult deformity, and pelvic ring traumatic fractures.

Company Profile

SI-BONE, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Santa Clara, US. The company is led by CEO Laura A. Francis. SIBN has traded publicly since 2018.

SI-BONE, Inc. Financial Trajectory

SI-BONE, Inc. (SIBN) reported $56.0M in revenue for Q2 FY2026, reflecting 6.5% growth compared to the prior quarter. The company recorded a net loss of $4.1M, with diluted EPS of $-0.09. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, SIBN averaged $-0.08 in diluted EPS.

How SI-BONE, Inc. Is Valued

SI-BONE, Inc. carries a market capitalization of $814M, placing it in the small-cap category. Analyst price targets span from $21.00 to $25.00, with a consensus of $23.00. At the current price of $18.35, that implies approximately 25% upside potential. Relative to its peer group, SIBN's quantitative score of 39/100 is below the peer average of 66/100.

Return on equity for SI-BONE, Inc. stands at -8.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -5.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -0.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 9.15 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -1.8%, the inverse of the P/E and a quick read on earnings relative to price.

SI-BONE, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 6.42 places it in the safe zone, indicating low near-term bankruptcy risk.

SI-BONE, Inc. has beaten Wall Street's EPS estimate in 8 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 37.1% above estimates on average.

Over the past six months, SI-BONE, Inc. insiders filed 57 SEC Form 4 transactions — 46 sales and 11 purchases. On net that is roughly 155K shares disposed (about $4.1M), a signal worth weighing alongside the fundamentals.

SIBN Financials

SIBN Latest News

SIBN Analyst Consensus

SIBN MoonshotScore

Common Questions About SIBN (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources